Celmatix
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
14 Wall St Ste 16D, New York City, New Y...Phone Number
(646) 315-6622Website
www.celmatix.comRevenue
$21.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Celmatix
Celmatix Inc. is a pioneering women's health biotech company based in the US, focused on developing novel therapeutics that leverage advances in female biology. Their product portfolio includes a first-in-class oral FSH receptor agonist aimed at improving fertility care, a novel JNK inhibitor for treating endometriosis, and early-stage AMH-targeting antibodies for ovarian folliculogenesis control. The company targets critical unmet needs in women's health, including conditions like endometriosis and Polycystic Ovary Syndrome (PCOS). Celmatix is committed to transforming women's health through innovative research and development.Explore more
Celmatix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celmatix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Celmatix has recently received funding, and reach out quickly before it becomes old news!
Celmatix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Celmatix had a recent Job posting/layoffs
Earning: See what the market has to say on Celmatix recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Celmatix
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Celmatix is spiking on competitors!
Funding: Get notified immidiatlly once Celmatix has new funding data
Product Launch: Get notified when Celmatix launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Celmatix
Find 2 more new buyers
Compare Similar Companies to Celmatix
Compare insights from companies similar to Celmatix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
-
-
Compare CEO
How does Piraye Beim compare against Competing Companies' CEOs?
PB
Piraye Beim
Founder & Chief Executive Officer at Celmatix
Top 40%
CEO effectiveness to drive business results
Excellent
0%
Good
100%
Average
0%
Poor
0%
Very Bad
0%
Good
100%Bad
0%VS.
PA
Peter Anevski
CEO at Progyny
Top 20%
CEO effectiveness to drive business results
Excellent
0%
Good
100%
Average
0%
Poor
0%
Very Bad
0%
Good
50%Bad
50%
Company Profile Activity
Activity Insights
Celmatix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Celmatix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Celmatix.
Celmatix financials insights
Gather financial insights about Celmatix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$806K
2012
Series A
$1.5M
2013
Private Equity
$4M
2014
Private Equity
$5.5M
2015
Private Equity
$3.8M
2016
Private Equity
$4.8M
Private Equity
$21M
2017
Other Financing Round
$12.5M
Celmatix Tech Stack
A closer look at the technologies used by Celmatix
Most Recent Scoops
Person-Based
Partnership
Person-Based
Events
Person-Based
Intellectual Property, Legal Affairs, Medical Research
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Celmatix News & Media
Celmatix : Names Mark Adams as Chief Information Officer - MarketScreener
Seasoned executive with deep experience in genomics, cloud computing, and data analytics to lead efforts to scale informatics systems ... -September 01, 2016 at 09:04 am EDT - MarketScreenerCelmatix Nominates First Lead Compound in Oral Fertility Drug Program
NEW YORK, NY, UNITED STATES, October 22, 2024 /EINPresswire.com/ -- Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, has announced the nomination of a lead compound in its oral Follicle Stimulating Hormone …Celmatix and Aché Laboratórios Announce Collaboration to Investigate a Novel Melatonin Receptor Agonists for Women’s Health
NEW YORK--(BUSINESS WIRE)--Celmatix Inc., a leading women’s health biotech focused on ovarian biology, and Aché Laboratórios, a leading Brazilian pharmaceutical company, today announced a collaboration and license option agreement to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Aché, for Women's Health indications. Today’s news follows Celmatix’s April announcement of the second of its three internal drug programs, targeting melatonin receptors ouCelmatix Announces Breakthrough in Novel Oral Fertility Drug Program
NEW YORK--(BUSINESS WIRE)--Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug. The innovative investigational product has the potential to revolutionize fertility treatments. The announcement coincides with the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE)
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Celmatix
Sign Up For FreeTo access detailed company insights
Celmatix Inc. is a pioneering women's health biotech company based in the US, focused on developing novel therapeutics that leverage advances in female biology. Their product portfolio includes a first-in-class oral FSH receptor agonist aimed at improving fertility care, a novel JNK inhibitor for treating endometriosis, and early-stage AMH-targetin... Read More
